Evidence map›Paper›PMID 36902537›Full record

ArticleJournal of clinical medicine2023

Assessing the Outcomes of Patients with Severe SARS-CoV-2 Infection after Therapeutic Plasma Exchange by Number of TPE Sessions.

Tamara Mirela Porosnicu, Dorel Sandesc, Daniel Jipa, Ciprian Gindac, Cristian Oancea, Felix Bratosin, Roxana Manuela Fericean, Shiva Charana Kodimala, Ciprian Nicolae Pilut, Laura Alexandra Nussbaum and 1 more

Full text read
In one paragraph

Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tamara Mirela PorosnicuDoctoral School, "Victor Babes" University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania.
Dorel SandescDepartment of Anesthesia and Intensive Care, "Victor Babes" University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania.
Daniel JipaIntensive Care Unit, "Pius Brinzeu" Emergency Clinical Hospital, 300041 Timisoara, Romania.
Ciprian GindacIntensive Care Unit, "Pius Brinzeu" Emergency Clinical Hospital, 300041 Timisoara, Romania.ORCID 0000-0003-0588-2121
Cristian OanceaCenter for Research and Innovation in Precision Medicine of Respiratory Disease, "Victor Babes" University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania.ORCID 0000-0003-2083-0581
Felix BratosinDepartment XIII, Discipline of Infectious Disease, "Victor Babes" University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania.ORCID 0000-0003-4711-4315
Roxana Manuela FericeanDepartment XIII, Discipline of Infectious Disease, "Victor Babes" University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania.ORCID 0000-0002-0776-0809
Shiva Charana KodimalaMediCiti Institute of Medical Sciences, NTR University of Health Sciences, Hyderabad 501401, India.
Ciprian Nicolae PilutDepartment of Microbiology, "Victor Babes" University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania.
Laura Alexandra NussbaumDepartment of Neurosciences, "Victor Babes" University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania.
Ioan Ovidiu SirbuCenter for Complex Network Sciences, "Victor Babes" University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania.ORCID 0000-0003-1618-9656

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The high mortality risk in severe SARS-CoV-2 infections is tightly correlated to the extreme elevation of inflammatory markers. This acute accumulation of inflammatory proteins can be cleared using plasma exchange (TPE), commonly known as plasmapheresis, although the available data on performing TPE in COVID-19 patients is limited regarding the optimal treatment protocol. The purpose for this study was to examine the efficacy and outcomes of TPE based on different treatment methods. A thorough database search was performed to identify patients from the Intensive Care Unit (ICU) of the Clinical Hospital of Infectious Diseases and Pneumology between March 2020 and March 2022 with severe COVID-19 that underwent at least one session of TPE. A total of 65 patients satisfied the inclusion criteria and were eligible for TPE as a last resort therapy. Of these, 41 patients received 1 TPE session, 13 received 2 TPE sessions, and the remaining 11 received more than 2 TPE sessions. It was observed that IL-6, CRP, and ESR decreased significantly after all sessions were performed in all three groups, with the highest decrease of IL-6 in those who received >2 TPE sessions (from 305.5 pg/mL to 156.0 pg/mL). Interestingly, there was a significant increase in leucocyte levels after TPE, but there was no significant difference in MAP changes, SOFA score, APACHE 2 score, or the PaO2/FiO2 ratio. The ROX index was significantly higher among the patients who underwent more than two TPE sessions, with an average of 11.4, compared to 6.5 in group 1 and 7.4 in group 2, which increased significantly after TPE. Nevertheless, the mortality rate was very high (72.3%), and the Kaplan-Meier analysis identified no significant difference in survival according to the number of TPE sessions. TPE can be used as last resort salvage therapy that can be regarded as an alternative treatment method when the standard management of these patients fails. It significantly decreases the inflammatory status measured via IL-6, CRP, and WBC, as well as demonstrating an improvement of the clinical status measured via PaO2/FiO2, and duration of hospitalization. However, the survival rate does not seem to change with the number of TPE sessions. Based on the survival analysis, one session of TPE as last resort treatment in patients with severe COVID-19 proved to have the same effect as repeated TPE sessions of 2 or more.

Indexed as

COVID-19plasmapheresisSARS-CoV-2therapeutic plasma exchange

Identifiers

PMID36902537
PMCPMC10003394

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read25
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.